INVESTORS
Three lines. The rest is a conversation.
Not a deck — a teaser. The full story lives across this site; here is why it's worth a call.
- 01The category
A defensible, category-creating product: an AI technician with write-access to PrimeRxthat no dashboard has. Every funded competitor watches claims through glass and recommends. SSVP has its hands on the keyboard and a licensed pharmacist’s signature on every move.
- 02The moat
Recurring, cash-protection revenue — money the pharmacy was about to lose — stacked on a payer-rules data flywheel. Every audit handled makes the next defense stronger, an asset human incumbents took decades to build, now accruing at software speed and impossible to backfill.
- 03The ask
Build capital for the 15-month build, weighted toward payer-rules knowledge engineering; pilot partners who want the overlay in their stores first; and channel introductions into independent pharmacy. No numbers here beyond what’s already public on this site.
If that’s a thesis you want to underwrite, the next step is a direct email — no gatekeeper.
deep@deepshah.tech